Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach

Amber Tong

Vaccines. Antibodies. Antivirals. The Covid-19 pandemic has given the world a crash course on the key medical tools that can protect humans from viruses. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Novo Nordisk’s amycretin prompts 22% weight loss in early obesity trial

Obesity biotech Aardvark files for IPO to advance oral, hunger-suppressing drug

Moderna information chief to retire next month; Pharming looks to Flagship for first new CEO since 2008

ALX Oncology to make case for accelerated approval with new evorpacept data in gastric cancer

As another Trump term gets underway, pharma advisors get comfortable with uncertainty

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Nasal sprays to stave off virus­es days at a time? J&J’s newest biotech part­ner draws $140M for 'proac­tive' ap­proach

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Nasal sprays to stave off viruses days at a time? J&J’s newest biotech partner draws $140M for 'proactive' approach